#PortfolioNews I Our #portfolio company ONA Therapeutics strengthens leadership to accelerate first-in-class #ADCs targeting resistant #cancer cells & advancing toward #clinical development.

📢 Read more here https://buff.ly/4gK9vh3

#Oncology #Biotech #Pharma #YsiosPortfolio

#PortfolioNews I Inbiomotion continues to expand its #international presence, with distribution partnerships spanning #Spain, #Portugal, #Italy, the #UK & Ireland, Sub-Saharan #Africa and now #SouthKorea.

👉https://buff.ly/OQsIayS

#vc #breastcancer #oncology #ysiosportfolio

📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊

🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need

👉 buff.ly/aO4iHwV

#YsiosPortfolio #vc

#YsiosNews I Ysios joins OnaTherapeutics $86.6M Series B to advance first-in-class #ADCs for treatment-resistant cancers.

✅ONA-255 #BreastCancer, toward clinical proof of concept
✅ONA-389 #ColorectalCancer

ysioscapital.com/2026/06/04/o...

#YsiosPortfolio #vc #biotech #barcelona

#PortfolioNews | Memo Therapeutics partners with CSL to advance recombinant polyclonal IgG, validating its DROPZYLLA® platform. 🚀🧬

👉 buff.ly/uCOUhUh

#YsiosPortfolio